Navigation Links
US, Russian organizations team to improve the quality of medicines
Date:4/7/2009

Rockville, Md., April 7, 2009 Aiming to improve the quality of medicines in the Russian Federation and the United States, two leading drug quality organizations in those countries today announced plans to work together on standards-related activities for drugs and their ingredients. These include efforts to reduce the availability of counterfeit and substandard medicines.

The agreement was captured in a Memorandum of Understanding (MOU) signed in Moscow by the Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (Roszdravnadzor) and the United States Pharmacopeial (USP) Convention. Roszdravnadzor is the surveillance agency for medicines and medical supplies within Russia's Ministry of Healthcare and Social Development. USP is an independent, non-profit organization that sets federally recognized quality standards in the United States for prescription and over-the-counter medications. It also sets widely recognized standards for food ingredients and dietary supplements.

"Access to good quality medicines is of critical importance to the public health, given the role that medicines play in saving lives, restoring health, and treating and preventing diseases," said Roger L. Williams, M.D., chief executive officer of USP. "Through a number of potential activities detailed in this agreement, Roszdravnadzor and USP will work to improve the quality of medicines that patients receive in Russia and the United States. This includes reducing the availability of counterfeit and substandard medicines, which pose a substantial threat to citizens of both countries and globally."

"With medicines and their ingredients coming from all over the world, international collaboration is a key part of protecting and enhancing the health of patients," said N.V. Yurgel, head of Roszdravnadzor. "We look forward to a productive relationship with USP that ultimately results in a safer drug supply."

Among the p
'/>"/>

Contact: Francine Pierson
fp@usp.org
301-816-8588
US Pharmacopeia
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Partnership to Prevent HIV Among Vulnerable Russian Youth
2. Movement Against Cancer, a Cancer Patient Advocacy Group in Russia, Launches an Effort to Inform Russian Authorities and the Public About Inadequate Access of Innovative and Effective Cancer Treatments for Cancer Patients in Russia
3. Number of Russian women smokers has doubled since Soviet collapse
4. Leading Russian Cancer Center Acquires CyberKnife(R) System
5. Russian research for FAIR
6. AIDS Organizations Support New HIV Testing Bill
7. Joplin Citizens and Health Organizations Call on Missouri Gov. Nixon for Study, Action on High Incidence of Birth Defects and Chronic Diseases in Community
8. Leading Healthcare Organizations Share Successes Realized with MEDais Predictive Analytics
9. Miami-Dade and Monroe County Organizations Receive Grants to JumpStart the Conversation
10. Komen Tulsa Affiliate Awards $420,000 to Local Organizations to Aid Breast Cancer Fight
11. Independent Review Organizations Take Pressure Off Healthcare Payers as Recession Deepens
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10VAs Health System Top Employer for AARP 58061 1VAs Health System Top Employer for AARP 58061 2Historic gene therapy trial to treat Alzheimers disease underway at Georgetown 58056 1Historic gene therapy trial to treat Alzheimers disease underway at Georgetown 58056 2Journalists invited to Darwin Chicago 2009 conference Oct 29 31 10039 1